MANAGEMENT OF BLADDER CANCER. A COMPREHENSIVE TEXT WITH CLINICAL SCENARIOS

•Authored by experts in their respective fields
•Provides a single, comprehensive reference source
•Useful resource for physicians
Management of bladder cancer provides a single, comprehensive reference source that incorporates all the latest information regarding bladder cancer. The text covers epidemiology and natural history of bladder cancer as well as latest findings regarding the genetics and molecular biology of the disease. Diagnostic and staging evaluation of both non-muscle invasive and invasive bladder cancer is discussed. The text incorporates chapters summarizing new findings regarding markers for the diagnosis of bladder cancer and new diagnostic techniques to enhance traditional methods such as cystoscopy. Risk stratified treatment of non muscle invasive bladder cancer including various approaches to intravesical therapy are reviewed. Current guideline based approaches to management and new data regarding diagnosis and prognostication of muscle invasive bladder cancer is analyzed and summarized. The application of chemotherapy for muscle invasive and advanced disease is discussed and the evidence based application of multimodality therapy highlighted. Finally, gaps in current knowledge and areas for future research are highlighted. Ongoing important clinical trials which could imminently yield significant new knowledge is discussed.
Authored by experts in their respective fields, Management of Bladder Cancer will serve as a easy and complete reference source for clinicians, researchers, individuals in training, allied health professionals and medical students in the fields of Urology, Medical Oncology, Radiation Oncology, Basic and Translational Science and Epidemiology.
Authors
•Badrinath R. Konety, MD, MBA, FACS. Professor and Chair, Dept. of Urology. Dougherty Family Chair in Urologic Oncology. Associate Director for Clinical Affairs, Masonic Cancer Center. University of Minnesota. MMC 394, 420 Delaware St. Minneapolis, USA.
•Sam S. Chang, MD, FACS. Professor of Urologic Surgery. Patricia and Rodes Hart Chair of Urologic Surgery. Department of Urologic Surgery. Vanderbilt University Medical Center. MCN A 1302, VUMC. Nashville,USA.
Table of contents (37 chapters)
1.Epidemiology and Natural History
2.Screening for Bladder Cancer
3.Pathology and Staging: Histopathology and Cytopathology
4.Pathology and Staging: Genetics and Molecular Biology
5.Imaging in Localized and Advanced Bladder Cancer
6.New Imaging Techniques in the Staging of Urothelial Carcinoma of the Bladder
7.Socioeconomic Issues and Improved Quality of Care
8.Quality of Life Measures
9.Prognostication and Risk Assessment
10.Clinical Trials and Emerging Therapeutic Strategies in Bladder Cancer
11.Improved Diagnostic Techniques
12.Clinical Scenario: Microscopic Hematuria and Atypical Cytology
13.Localized Surgical Therapy and Surveillance
14.Clinical Scenario: Initial High-Grade Ta Tumor
15.Clinical Scenario: Recurrent Ta Tumor
16.Clinical Scenario: Rapidly Growing, High Volume, Low-Grade Ta Tumor
17.Clinical Scenario: Low-Grade T1 Tumor
18.Intravesical Therapy
19.Clinical Scenario: Initial CIS
20.Management of BCG Recurrent Bladder Cancer
21.Clinical Scenario: Persistent CIS and High-Grade Ta Bladder Cancer After BCG
22.Clinical Scenario: Management of Side Effects from Bacillus Calmette-Guérin Bladder Instillation
23.Guideline-Based Management of Non-muscle Invasive Bladder Cancer: Comparison of the AUA, EAU, ICUD, and NCCN Guidelines
24.Open Radical Cystectomy
25.Robotic Cystectomy
26.Clinical Scenario: T2 Bladder Tumor
27.Urinary Diversion: Open and Robotic Techniques
28.Chemoradiotherapy
29.Clinical Scenario: Bladder Preservation
30.Management of Bladder Cancer, Role of Chemotherapy and Controversies Surrounding Its Application
31.Clinical Scenario: Large Volume, Non-metastatic T2 Bladder Tumor
32.The Role of Pelvic Lymphadenectomy at the Time of Radical Cystectomy for Bladder Cancer
33.Clinical Scenario: Unexpected Positive Nodes at Radical Cystectomy
34.Surveillance and Monitoring
35.Clinical Scenario: The Role of Perioperative Chemotherapy
36.Clinical Scenario: Clinical Pelvic Nodal Metastases
37.Guideline-Based Management of Muscle-Invasive Bladder Cancer: NCCN, ICUD, and EAU